The CARE-ROP study identified ranibizumab as an effective treatment to control acute retinopathy of prematurity (ROP), an eye disease that affects preterm babies. For 16 preterm children entering the follow-up period, their ophthalmologic- and neurodevelopment was assessed at the one-year and two-year visits post-baseline. The patients’ outcomes of ranibizumab usage are very reassuring regarding long-term safety. Yet, late reactivation of ROP can represent a challenge and calls for regular follow-ups. Retinopathy of prematurity is…